Search Result

Results for "

Cd40 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Cytochrome P450 (1) Fluorescent Dye (1) Interleukin Related (1) JAK (1) NF-κB (1) PI3K (1) TNF Receptor (17)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Inflammation/Immunology (13) Metabolic Disease (4)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Targets Recommended: Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122663A

BIO8898	TNF Receptor Apoptosis	Metabolic Disease
BIO8898 is a potent *CD40-CD154* inhibitor. BIO8898 inhibits soluble CD40L binding to CD40-Ig with an IC₅₀ value of 25 µM. BIO8898 inhibits CD40L-induced apoptosis .

HY-P99257

Bleselumab ASKP 1240	TNF Receptor	Inflammation/Immunology
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (K_d: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .

HY-P990111

BMS-986325 (anti-CD40)	TNF Receptor	Inflammation/Immunology
BMS-986325 (anti-CD40) is a CD40 inhibitor, and can be used for primary Sj gren's syndrome research .

HY-122663

(Rac)-BIO8898	TNF Receptor	Cancer
(Rac)-BIO8898 is a CD40-CD154 co-stimulatory interaction inhibitor. (Rac)-BIO8898 inhibits CD154 binding to CD40-Ig with an IC₅₀ of 25 μM .

HY-P99842A

Dapirolizumab	TNF Receptor	Inflammation/Immunology
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .

HY-110247

TRAF-STOP inhibitor 6877002 1 Publications Verification	TNF Receptor NF-κB	Cardiovascular Disease Inflammation/Immunology
TRAF-STOP inhibitor 6877002 is a selective *CD40-TRAF6* interaction inhibitor. TRAF-STOP inhibitor 6877002 exerts anti-atherosclerotic activity by blocking the CD40-TRAF6 signaling pathway, inhibiting classical monocyte activation, leukocyte recruitment, and macrophage activation and migration. TRAF-STOP inhibitor 6877002 reduces the phosphorylation levels of signaling intermediates in the canonical NF-κB pathway .

HY-154821A

DRI-C21041 (DIEA)	TNF Receptor	Inflammation/Immunology
DRI-C21041 DIEA is a *CD40/CD40L* interaction inhibitor, with an IC₅₀ of 0.31 μM. DRI-C21041 DIEA inhibits the immune response induced by alloantigen .

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Metabolic Disease Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the **CD40 ligand (CD40L)** with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .

HY-P10399

KGYY15 Mouse KGYY15; KGYY15 peptide	TNF Receptor	Metabolic Disease
KGYY15 (Mouse KGYY15) is a CD40 targeting peptide, which weakly inhibits the CD40-CD40L interaction with IC₅₀ of more than 1mM. KGYY15 activates 33% NF-κB pathway at 100 μM .

HY-154821

DRI-C21041	TNF Receptor	Inflammation/Immunology
DRI-C21041 is a *CD40/CD40L* interaction inhibitor, with an IC₅₀ of 0.31 μM. DRI-C21041 inhibits the immune response induced by alloantigen .

HY-125025

SMI 6860766	TNF Receptor	Metabolic Disease Inflammation/Immunology
SMI 6860766, a small molecule inhibitor of CD40-TRAF6 interaction, improves glucose tolerance, reduces immune cell accumulation in adipose tissue, and reduces AT inflammation .

HY-154822

DRI-C25441	TNF Receptor	Inflammation/Immunology
DRI-C25441 is a potent blocker of CD40 and CD40L interaction, with an IC₅₀ of 0.36 μM. DRI-C25441 can inhibit the immune response induced by alloantigen .

HY-D1124

Mordant brown 1	Fluorescent Dye	Others
Mordant brown 1, a naphthalenesulphonic acid derivative, is an azo dye. Mordant brown 1 is also an effective and specific inhibitor of CD40-CD154 costimulatory protein-protein interaction .

HY-120323

DRI-C21045 1 Publications Verification	TNF Receptor	Inflammation/Immunology
DRI-C21045 (compound 10) is a potent and selective inhibitor of the *CD40-CD40L* costimulatory protein-protein interaction (PPI) with an IC₅₀ of 0.17 µM. DRI-C21045 shows concentration-dependent inhibition of the activation of NF-κB and B cell proliferation all induced by CD40L with IC₅₀s of 17.1 µM and 4.5 µM, respectively .

HY-131968

BMS-986202	JAK Cytochrome P450	Inflammation/Immunology
BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-P990134

Anti-Mouse CD40L/CD154 Antibody (MR-1)	TNF Receptor	Others
Anti-Mouse CD40L/CD154 Antibody (MR-1) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD40L/CD154.

HY-P990133

Anti-Monkey/Human CD40L/CD154 Antibody (5C8)	TNF Receptor	Others
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is a mouse-derived IgG2a type antibody inhibitor, targeting to monkey/human CD40L/CD154.

HY-P990270

Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)	TNF Receptor	Others
Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse CD40L/CD154.

HY-P990269

Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)	TNF Receptor	Others
Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD40L/CD154.

HY-16668

Tyrphostin A1 1 Publications Verification Tyrphostin 1; AG9	Interleukin Related	Inflammation/Immunology
Tyrphostin A1(AG9) inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells.

HY-120471

AM-0687	PI3K	Inflammation/Immunology
AM-0687 is a selective inhibitor for PI3Kδ with an IC₅₀ of 2.9 nM. AM-0687 decreases the levels of IgG and IgM specific antibodies, inhibits the anti-IgM/CD40L-induced proliferation of human B cell (IC₅₀=0.8 nM) and the phosphorylation of AKT (IC₅₀=0.7 nM), and exhibits anti-inflammatory efficacy .

Cat. No.	Product Name	Type

HY-D1124

Mordant brown 1	Dyes
Mordant brown 1, a naphthalenesulphonic acid derivative, is an azo dye. Mordant brown 1 is also an effective and specific inhibitor of CD40-CD154 costimulatory protein-protein interaction .

Cat. No.	Product Name	Target	Research Area

HY-P10399

KGYY15 Mouse KGYY15; KGYY15 peptide	TNF Receptor	Metabolic Disease
KGYY15 (Mouse KGYY15) is a CD40 targeting peptide, which weakly inhibits the CD40-CD40L interaction with IC₅₀ of more than 1mM. KGYY15 activates 33% NF-κB pathway at 100 μM .

Cat. No.	Product Name	Target	Research Area

HY-P99257

Bleselumab ASKP 1240	TNF Receptor	Inflammation/Immunology
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (K_d: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection .

HY-P990111

BMS-986325 (anti-CD40)	TNF Receptor	Inflammation/Immunology
BMS-986325 (anti-CD40) is a CD40 inhibitor, and can be used for primary Sj gren's syndrome research .

HY-P99842A

Dapirolizumab	TNF Receptor	Inflammation/Immunology
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .

HY-P99625

Frexalimab SAR441344; INX-021	TNF Receptor	Metabolic Disease Inflammation/Immunology
Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the **CD40 ligand (CD40L)** with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj gren’s syndrome and type I diabetes research .

HY-P990134

Anti-Mouse CD40L/CD154 Antibody (MR-1)	TNF Receptor	Others
Anti-Mouse CD40L/CD154 Antibody (MR-1) is a Armenian hamster-derived IgG type antibody inhibitor, targeting to mouse CD40L/CD154.

HY-P990133

Anti-Monkey/Human CD40L/CD154 Antibody (5C8)	TNF Receptor	Others
Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is a mouse-derived IgG2a type antibody inhibitor, targeting to monkey/human CD40L/CD154.

HY-P990270

Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1)	TNF Receptor	Others
Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse CD40L/CD154.

HY-P990269

Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1)	TNF Receptor	Others
Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD40L/CD154.

Cat. No.	Product Name	Chemical Structure

HY-131968

BMS-986202
BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

BMS-986202

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: